Ayesha A Shafi
Overview
Explore the profile of Ayesha A Shafi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
Oncogene
. 2024 Sep;
43(43):3197-3213.
PMID: 39266679
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
2.
Sardar S, McNair C, Ravindranath L, Chand S, Yuan W, Bogdan D, et al.
bioRxiv
. 2024 May;
PMID: 38766099
Castration resistant prostate cancer (CRPC) remains an incurable disease stage with ineffective treatments options. Here, the androgen receptor (AR) coactivators CBP/p300, which are histone acetyltransferases, were identified as critical mediators...
3.
Nelson N, Burke S, Cappelli L, Matlack L, Smith A, Francois N, et al.
Clocks Sleep
. 2024 Mar;
6(1):200-210.
PMID: 38534802
The circadian system, a vital temporal regulator influencing physiological processes, has implications for cancer development and treatment response. Our study assessed circadian timing's impact on whole-brain radiotherapy outcomes in brain...
4.
Gordon N, Gallagher P, Neupane N, Mandigo A, McCann J, Dylgjeri E, et al.
bioRxiv
. 2023 Mar;
PMID: 36993449
Results: Two distinct CRPC models were found to be sensitive to physiologically relevant doses of ascorbate. Moreover, additional studies indicate that ascorbate inhibits CRPC growth via multiple mechanisms including disruption...
5.
Pence S, Chesnut G, Shafi A
Urology
. 2023 Jan;
175:6-12.
PMID: 36693529
The human body was evolutionarily programmed to run on cycles, termed circadian rhythms, which integrate human behavior and bodily function with the environment. Disruptions to these rhythms via desynchronization have...
6.
Basil P, Robertson M, Bingman 3rd W, Dash A, Krause W, Shafi A, et al.
Sci Rep
. 2022 Mar;
12(1):5351.
PMID: 35354884
The constitutively active androgen receptor (AR) splice variant, AR-V7, plays an important role in resistance to androgen deprivation therapy in castration resistant prostate cancer (CRPC). Studies seeking to determine whether...
7.
Dylgjeri E, Kothari V, Shafi A, Semenova G, Gallagher P, Guan Y, et al.
Clin Cancer Res
. 2022 Jan;
28(7):1446-1459.
PMID: 35078861
Purpose: DNA-dependent protein kinase catalytic subunit (DNA-PKcs, herein referred as DNA-PK) is a multifunctional kinase of high cancer relevance. DNA-PK is deregulated in multiple tumor types, including prostate cancer, and...
8.
McCann J, Vasilevskaya I, McNair C, Gallagher P, Neupane N, de Leeuw R, et al.
Oncogene
. 2021 Nov;
41(3):444-458.
PMID: 34773073
The tumor suppressor gene TP53 is the most frequently mutated gene in numerous cancer types, including prostate cancer (PCa). Specifically, missense mutations in TP53 are selectively enriched in PCa, and...
9.
Mandigo A, Shafi A, McCann J, Yuan W, Laufer T, Bogdan D, et al.
Cancer Res
. 2021 Oct;
82(2):221-234.
PMID: 34625422
The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1...
10.
Mandigo A, Yuan W, Xu K, Gallagher P, Pang A, Guan Y, et al.
Cancer Discov
. 2021 Apr;
11(9):2334-2353.
PMID: 33879449
Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming biological networks that drive cancer progression, although mechanistic insight has been largely limited to the impact...